News | October 11, 2013

New Data Shows Corus CAD Reduces Unnecessary Cardiac Testing

Test may reduce cost for women with symptoms suggestive of obstructive coronary artery disease

blood testing cardiodx corus cad coronary artery disease

October 11, 2013 — CardioDx Inc. announced results of two studies indicating that Corus CAD, a blood-based gene expression test, may help reduce unnecessary cardiac testing and costs by aiding clinician decision-making in the evaluation of women with obstructive coronary artery disease (CAD) symptoms. The studies were presented at The North American Menopause Society (NAMS) 2013 Annual Meeting in Dallas, Texas.

The first study, "The Clinical Utility of a Novel Genomic-Based, Gene Expression Test in a Registry Study of Women Evaluated for Symptoms Suggestive of Obstructive Coronary Artery Disease in the Ambulatory Care Setting: Results from the REGISTRY I Study," included a total of 180 female patients who possessed non-acute symptoms suggestive of obstructive CAD at six community-based primary care practices. The primary outcome in this pre-specified, subgroup analysis was the association between the Corus CAD score, ranging from 1 to 40, and referrals to noninvasive and invasive cardiac testing among female patients based on the test score. The study found that each 10-point decrease in the Corus CAD score was associated with a 13-fold decrease in the likelihood of referral for further cardiac testing (P < 0.001). Furthermore, the observed rate of referrals in low-scoring patients (</= 15) was 5 percent, 94 percent lower than the referral rate seen in elevated-score patients (> 15) (P < 0.001). The results of this study suggest that real-world use of Corus CAD in primary care practices early in the assessment of obstructive CAD may help optimize patient care and reduce unnecessary cardiac testing.

“Our study of a real-world registry found that a sex-specific, blood-based gene expression test may help clinicians quickly and accurately eliminate obstructive CAD as the cause of their patients' symptoms early in the stream of care, thereby allowing them to investigate other origins of patients' symptoms," said Joseph Ladapo, M.D., Ph.D., and assistant professor of medicine, department of population health and medicine, New York University School of Medicine.

A second study presented at the meeting focused on the potential economic savings of using Corus CAD early in the stream of care to evaluate patients with suspected CAD. The study included 57 female patients, without known CAD, presenting with non-acute chest pain and atypical obstructive CAD symptoms. A change in cardiac diagnostic testing strategy was noted in 34 women (60 percent) post-Corus CAD testing (P < 0.001). When per-procedure costs were applied to the study results, a 22 percent savings in cardiac diagnostic testing costs was realized. Cardiac test utilization in the 57 women showed a pattern of decreased testing costs post-Corus CAD scores versus the matched control group ($2,504 per patient versus $1,960), yielding a $544 per-patient cost-savings in cardiac diagnostic testing.

For more information: www.cardiodx.com

Related Content

Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
Overlay Init